The DFS readout in 1H 2026 is the next major catalyst. The reduced event rate (fewer progressions/deaths) could suggest clinical benefit, but confirmation awaits unblinding. Investors should monitor upcoming presentations at World Vaccine Congress (April 1) and AACR (April 21) for additional immunogenicity data. Cash runway appears secure through the readout, reducing near-term dilution risk.
Price Chart
Executive Summary
Elicio Therapeutics reported its 2025 financial results and provided updates on its Phase 2 AMPLIFY-7P trial for ELI-002 7P in pancreatic cancer. The company noted fewer disease progressions and deaths than expected, extending its cash runway into Q3 2026, beyond the anticipated event-driven primary disease-free survival (DFS) analysis in 1H 2026. No revenue was generated, as the company remains clinical-stage.
Key Financial Metrics
Key Facts
- Event-driven primary DFS analysis for the Phase 2 AMPLIFY-7P trial expected in 1H 2026
- Fewer disease progressions and deaths observed than projected, though trial remains blinded
- Cash and cash equivalents were $18.6 million as of December 31, 2025, up from $17.6 million in 2024
- Company raised $4.9M in Q4 2025 and $6.3M in Q1 2026 via at-the-market program
- Projected cash runway into Q3 2026, sufficient to cover the DFS readout
- R&D expenses decreased to $24.9M in 2025 from $33.7M in 2024 due to lower clinical costs
- Net loss narrowed to $39.5M in 2025 from $51.9M in 2024; net loss per share was $2.58 vs. $4.25
Financial Impact
Reduced R&D spend by $8.8M YoY, narrowing net loss by $12.3M. Cash increased by $1M despite losses, supported by ATM raises totaling $11.2M in Q4 2025 and Q1 2026.
Risk Factors
- Clinical trial remains blinded — positive interpretation of fewer events is speculative
- No revenue or profitability in foreseeable future; dependent on capital raises
- Previous warrant liability adjustments added $1.9M non-cash expense, indicating complex capital structure
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3255089 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 18d ago | DEF 14A | $1.88 | awaiting T+60 | — | $1.83 (−2.66%) |
Sep 22, 2026 5w ago | Institutional Cluster | $1.87 | awaiting T+60 | — | $1.83 (−2.14%) |
Jul 2, 2026 16w ago | 424B5 | $3.22 $1.88 | ▲ +41.61% | ▲ +44.62% | $1.83 (+43.17%) |
Jul 2, 2026 16w ago | 8-K | $3.22 $1.88 | ▲ +41.61% | ▲ +44.62% | $1.83 (+43.17%) |
Jun 24, 2026 17w ago | 8-K | $3.75 $1.89 | ▼ −49.60% | ▼ −53.33% | $1.83 (−51.20%) |
Jun 17, 2026 18w ago | 8-K | $4.71 $2.05 | ▼ −56.48% | ▼ −59.62% | $1.83 (−61.15%) |
May 11, 2026 24w ago | 8-K | $10.55 $3.14 | ▼ −70.24% | ▼ −74.62% | $1.83 (−82.65%) |
Mar 17, 2026 32w ago | EFFECT | $12.18 $14.20 | ▲ +16.58% | ▲ +6.72% | $1.83 (−84.98%) |
Mar 12, 2026 32w ago | Press Release | $12.20 $13.55 | ▲ +11.07% | ▼ −0.55% | $1.83 (−85.00%) |
Mar 2, 2026 34w ago | S-3/A | $12.50 $10.77 | ▲ +13.84% | ▲ +24.16% | $1.83 (+85.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers